ENDRA director granted 60,324 RSUs

ENDRA Life Sciences director Lou Basenese received a stock-based award from the company.

Rhea-AI Filing Summary

ENDRA Life Sciences director Lou Basenese received a stock-based award from the company. On January 21, 2026, he was granted 60,324 shares of common stock in the form of restricted stock units (RSUs) at a grant price of $0 per share. Each RSU converts into one share of common stock.

The RSUs will vest in full on January 21, 2027, meaning they convert to common shares on that date if vesting conditions are met. After this grant, Basenese beneficially owned a total of 65,709 shares of ENDRA Life Sciences common stock, which the disclosure notes includes unvested RSUs, all held directly.

Insider Trade Summary

Grant/Award: 60,324 shares

Grant/Award 1 txn

Insider Basenese Lou

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	60,324	$0.00	$0.00

Holdings After Transaction: Common Stock — 65,709 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.
2. F2. Includes unvested RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ENDRA Life Sciences (NDRA) report for Lou Basenese?

ENDRA Life Sciences reported that director Lou Basenese acquired 60,324 shares of common stock on January 21, 2026 through a grant of restricted stock units (RSUs) at a price of $0 per share.

What type of shares did Lou Basenese receive in this NDRA Form 4 filing?

The award consists of restricted stock units (RSUs) that each convert into one share of ENDRA Life Sciences common stock on a one-for-one basis.

When do Lou Basenese’s RSUs in ENDRA Life Sciences (NDRA) vest?

The disclosure states that the RSUs will vest in full on January 21, 2027, at which point they convert into common shares, subject to applicable vesting conditions.

How many ENDRA Life Sciences (NDRA) shares does Lou Basenese beneficially own after the transaction?

Following the reported grant, Lou Basenese beneficially owned 65,709 shares of ENDRA Life Sciences common stock, held directly. This total includes unvested RSUs according to the footnote.

Did Lou Basenese buy ENDRA Life Sciences (NDRA) shares on the open market?

No. The Form 4 indicates a transaction code “A” for acquisition, reflecting a stock grant of RSUs at $0 per share, rather than an open-market purchase.

What is Lou Basenese’s relationship to ENDRA Life Sciences (NDRA)?

The filing identifies Lou Basenese as a director of ENDRA Life Sciences Inc., and the Form 4 is filed as a single reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 07:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Basenese Lou

(Last) (First) (Middle)

C/O ENDRA LIFE SCIENCES INC.

3600 GREEN COURT, SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		60,324(1)	A	$0	65,709(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2027.

2. Includes unvested RSUs.

	/s/ Lou Basenese by Mark Busch, attorney-in-fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.